ArticleFrontiers in oncology2026
An investigational prognostic framework for stage IVB cervical cancer based on metastatic patterns: a population-based study with exploratory external evaluation.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current staging system classifies all patients with metastatic cervical cancer as stage IVB, without accounting for prognostic heterogeneity. This study aimed to develop an exploratory metastatic pattern-based framework for prognostic stratification within stage IVB cervical cancer. Methods: Patients with Results: Brain, liver, lung, and bone metastases were identified as the main metastatic determinants of prognosis. Based on their prognostic contributions and combinations, patients were categorized into three subgroups: stage IVB1 (metastases excluding brain, liver, lung, or bone), stage IVB2 (metastases excluding brain, including one of liver, lung, or bone, or combinations of liver and bone, or lung and bone), and stage IVB3 (metastases to the brain, or concurrent liver and lung). The three groups showed distinct survival patterns in the training and internal validation cohorts. In the external cohort, the overall prognostic ordering was similar; however, validation of the IVB3 category remained exploratory owing to its limited representation. In exploratory subgroup analyses, chemoradiotherapy was associated with longer survival than chemotherapy alone in stage IVB1 and stage IVB2, whereas no significant survival difference was observed between these approaches in stage IVB3. Conclusion: The proposed IVB1-IVB3 classification represents an investigational prognostic framework for characterizing heterogeneity within stage IVB cervical cancer. Treatment-related findings were observational and hypothesis-generating and should not be interpreted as evidence of treatment benefit. Prospective multicenter studies are required before this framework can be considered for clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.